Novartis CEO Backs Malaria Drug Against COVID-19
Also Testing Jakavi, Gilenya And Ilaris
Executive Summary
A coronavirus vaccine is some way off and until then, Vas Narasimhan, head of Novartis, is thinking that of the drugs being repurposed to treat COVID-19, hydroxychloroquine looks best placed to provide the quickest benefit.
You may also be interested in...
Sandoz Unveils Zero-Profit COVID-19 Portfolio
Lutz Hegemann, chief operating officer for global health at Novartis, says the project will continue until a vaccine or curative treatments have reached the world's poorest places, not just until they are first approved in a high income country.
Novartis Unveils Zero Profit COVID-19 Drugs Portfolio
Lutz Hegemann, chief operating officer for global health at Novartis, tells Scrip the project will continue until a vaccine or curative treatments have reached the world's poorest places, not just until they are first approved in a high income country.
Pharma Can Reset Reputation In Pandemic, Says Novartis CEO
Vas Narasimhan hopes that donations and the "unprecedented collaborations" between drugmakers trying to overcome the COVID-19 pandemic is leading to a shift in the perception of the value of the sector to society.